Remogliflozin etabonate (GSK189075) 是一种具有口服活性、选择性和低亲和力的钠葡萄糖协同转运蛋白 (SGLT2) 抑制剂，对 hSGLT2、rSGLT2、hSGLT1、rSGLT1 的 Ki 值分别为 1.95 μM、2.14 μM、43.1 μM、8.57 μM。
| Cas No. | 442201-24-3 |
| 别名 | GSK189075 |
| Canonical SMILES | CC(C)OC1=CC=C(CC2=C(C)N(C(C)C)N=C2O[C@@H]3O[C@H](COC(OCC)=O)[C@@H](O)[C@H](O)[C@H]3O)C=C1 |
| 分子式 | C26H38N2O9 |
| 分子量 | 522.6 |
| 溶解度 | DMSO: Soluble,Methanol: Soluble |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Remogliflozin etabonate is a prodrug form of the sodium-glucose transporter 2 (SGLT2) inhibitor remogliflozin A . Remogliflozin etabonate inhibits human SGLT2 and SGLT1 (Kis = 1.95 and 43.1 μM, respectively). It inhibits increases in plasma glucose levels in a glucose tolerance test in a rat model of diabetes induced by streptozotocin when administered at doses of 3 and 10 mg/ml. Remogliflozin etabonate (10 and 30 mg/kg twice per day for 6 weeks) also increases fasting plasma insulin levels and reduces fasting plasma glucose and triglyceride levels, as well as urinary glucose excretion, in a db/db mouse model of diabetes with hyperinsulinemia and obesity. |
